Cardio Diagnostics Holdings, Inc. (CDIOW) 股票分析

公司概述

Cardio Diagnostics Holdings, Inc. is a specialized biotechnology entity focused on the development and commercialization of epigenetics-based clinical tests designed to assess risk for cardiovascular disease, specifically offering the Epi+Gen CHD test for symptomatic coronary heart disease and Precisio diagnostics. Although the company operates within the broader healthcare and biotechnology landscape, the specific sector and industry classifications are not publicly disclosed in current filings, which suggests the firm may be operating in a niche sub-sector of medical diagnostics rather than a standardized industry category. The company maintains a very small operational scale with a total of 15 employees and a market capitalization and annual revenue that are currently not quantified in standard valuation metrics, indicating a pre-revenue or micro-cap status. This lack of a defined market cap and revenue figure implies that the company is likely in an early developmental stage where traditional financial benchmarks are not yet applicable, and its financial position relies heavily on future product commercialization rather than established market share or significant revenue generation.

财务健康

The company reported a trailing twelve-month revenue of $14,825, yet it simultaneously recorded a net loss of $-6,498,167 and an EBITDA of $-6,085,950, revealing a severe structural divergence where operating costs vastly exceed revenue generation. The free cash flow stands at $-3,809,743, indicating that the company is burning through its limited liquidity reserves rapidly, which severely constrains its financial flexibility and necessitates external capital raises to sustain operations. Margin analysis shows an extreme gross margin of 100.0%, likely due to minimal cost of goods sold in the current stage, contrasted with an operating margin of -41159.6% and a profit margin of 0.0%, which highlights that overhead expenses and R&D costs are disproportionately high relative to the current revenue base. Despite the negative earnings, the balance sheet shows cash holdings of $5.11M against a debt obligation of $695,619, resulting in a debt-to-equity ratio of 9.97, which suggests a highly leveraged capital structure where equity is minimal relative to liabilities. The current ratio is reported at 9.79, indicating that short-term assets are sufficient to cover short-term liabilities many times over, providing a buffer against immediate liquidity crises despite the cash burn. Return on equity is -78.6% and return on assets is -44.1%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns, a common characteristic for early-stage biotech firms before product approval and sales scale.

估值评估

Trailing P/E and forward P/E ratios are both unavailable (N/A), implying that the market cannot value the stock based on current or expected earnings multiples due to the company's persistent losses and lack of profitability. The price-to-book ratio is 0.00, indicating that the market capitalization is so low relative to the company's book value that the stock trades at a significant discount, effectively pricing in a high probability of dilution or liquidation risk. Since price-to-sales and EV/EBITDA metrics are not available, traditional alternative valuation models cannot be applied to assess the company's intrinsic value relative to its sales or cash flow generation capabilities. The stock has a 52-week high and low of $0.02, meaning the current trading price is static at the bottom of its observed range, suggesting a lack of recent upward price momentum or market interest. With a beta of 2.66, the stock exhibits extreme volatility, moving more than double the magnitude of the broader market, which introduces significant risk for traders and investors sensitive to market fluctuations.

Growth & Income

Revenue growth year-over-year is -21.2%, while earnings growth is not applicable (N/A) due to the absence of profitable earnings in the prior period, indicating that the company is currently shrinking in top-line sales while remaining deeply unprofitable. As the company does not pay a dividend, there is no dividend yield or payout ratio to analyze, meaning the firm is not distributing cash to shareholders and theoretically retains all available cash, although currently negative, for reinvestment into its clinical trials and product development. The overall growth and income profile is characterized by declining revenue and zero income distribution, reflecting a high-risk environment typical of pre-commercial biotechnology assets that have yet to achieve product-market fit or regulatory approval for their cardiovascular disease testing platforms.